Amesite Inc. launched NurseMagic™ EMR, enhancing its AI-driven platform for post-acute care with modular capabilities and flexible integration.
Quiver AI Summary
Amesite Inc. announced the launch of its NurseMagic™ EMR, significantly enhancing its platform after a year of strong revenue growth. This AI-native electronic medical record (EMR) system expands NurseMagic™ capability from a point-of-care solution to a core post-acute care infrastructure, which can work with existing systems or replace them entirely. The company's revenue increased notably with the introduction of higher-tier products, including a 2.4x rise after launching Teams+ and an 82% increase in the fourth quarter following the launch of the Enterprise tier. The U.S. post-acute care market is projected to grow substantially, driven by factors like an aging population. Amesite's NurseMagic™ is gaining traction in this market, with a 1,400% increase in website visits reflecting growing interest in AI solutions. The launch of the EMR reinforces Amesite's commitment to providing flexible, impactful solutions that meet customer needs in the healthcare space.
Potential Positives
- Launch of the NurseMagic™ EMR significantly expands Amesite's platform capabilities, positioning the company for greater market penetration in the growing post-acute care segment.
- The EMR's flexible integration with existing systems or complete replacement options strengthens Amesite's competitive position and appeal to customers.
- Demonstrated strong sequential revenue growth, including 82% increase in Q4 revenues and 69% quarter-over-quarter growth in Q1 fiscal 2026, indicating robust demand for the company's offerings.
- Increased website visits by nearly 1,400% since January 2025 suggest rising awareness and interest in Amesite's AI solutions among potential customers.
Potential Negatives
- The press release heavily relies on forward-looking statements, indicating potential risks and uncertainties about future performance that may concern investors.
- Despite reported revenue growth, the emphasis on generative AI's value and the competitive nature of the market suggests that Amesite may face significant competition, which could impact future sales and market position.
- The mention of needing to integrate or replace legacy systems implies that potential customers might experience disruption during the onboarding process, which could deter some clients from adopting the NurseMagic™ EMR.
FAQ
What is the NurseMagic™ EMR?
The NurseMagic™ EMR is an AI-native, modular electronic medical record system designed for post-acute care environments.
When will the NurseMagic™ EMR start onboarding customers?
Amesite plans to begin onboarding EMR customers in January 2026.
How has Amesite’s revenue changed since launching NurseMagic™?
Amesite reported a significant revenue increase following the launch of higher-value product tiers, including a 2.4x growth after launching Teams+.
What markets does NurseMagic™ serve?
NurseMagic™ currently serves post-acute providers in home health, hospice, skilled nursing, senior living, and home care sectors.
What advantages does NurseMagic™ EMR offer to users?
The NurseMagic™ EMR provides flexibility by coexisting with legacy systems or fully replacing them, ensuring operational continuity and cost savings.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMST Hedge Fund Activity
We have seen 7 institutional investors add shares of $AMST stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC added 29,898 shares (+inf%) to their portfolio in Q3 2025, for an estimated $91,188
- CITADEL ADVISORS LLC removed 22,992 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $61,848
- TWO SIGMA SECURITIES, LLC removed 10,589 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,484
- HRT FINANCIAL LP removed 10,438 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $28,078
- OSAIC HOLDINGS, INC. added 10,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $30,500
- TWO SIGMA INVESTMENTS, LP removed 5,728 shares (-26.5%) from their portfolio in Q3 2025, for an estimated $17,470
- KOVITZ INVESTMENT GROUP PARTNERS, LLC added 2,640 shares (+1.6%) to their portfolio in Q3 2025, for an estimated $8,051
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DETROIT, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST) today announced the launch of the NurseMagic™ EMR, marking a significant expansion of the Company’s platform following a year of strong sequential revenue growth and enterprise traction. The AI-native, modular EMR extends NurseMagic™ from a point-of-care solution into core post-acute care infrastructure, supporting both coexistence with legacy systems and full system replacement. Amesite expects to begin onboarding EMR customers in January 2026.
Amesite’s revenue growth has occurred in clear step changes aligned with the rollout of progressively higher-value product tiers, progressing from Individual to Teams, Teams+, and Enterprise offerings. Following the May 2025 launch of Teams+ , the Company reported a 2.4x increase in quarterly revenue . With the July 2025 introduction of its Enterprise tier , priced on patient census rather than individual users, revenues increased 82% in the fourth quarter. Continued expansion of Enterprise capabilities and industry outreach drove an additional 69% quarter-over-quarter revenue increase in the first quarter of fiscal 2026.
McKinsey estimates that generative AI could create $2.6 trillion to $4.4 trillion in annual economic value, primarily when AI is embedded into core operating systems rather than used as standalone tools. 1 In under 18 months since its June 2024 public launch, NurseMagic™ has progressed from an AI assistant for individual clinicians to an enterprise platform with census-based pricing and now an AI-native EMR.
The U.S. post-acute care market is one of healthcare’s largest and fastest-growing segments, valued at more than $470 billion in 2024 and projected to exceed $850 billion in the coming years. Growth is driven by an aging population, rising chronic disease burden, and sustained payer and policy shifts toward lower-cost, home-based care models. 2 Technology-enabled post-acute care has demonstrated meaningful cost savings and clinical outcomes. 3 NurseMagic™ currently serves post-acute providers across home health, hospice, skilled nursing, senior living, and home care.
“What makes this launch particularly powerful from a sales perspective is the flexibility it gives our customers, and how it strengthens our position in the market,” said Brandon Owens, VP of Sales at Amesite. “We can work alongside existing EMRs, delivering immediate operational and financial impact without disruption, or we can replace them entirely with a full AI‑native EMR built for how post‑acute care operates today. That optionality changes the dynamic in every conversation. Buyers don’t have to choose between incremental improvement and wholesale change. In competitive situations, that’s a very strong position to sell from, and one that legacy systems simply can’t match.”
“Since January 2025, website visits have increased by nearly 1,400%, reflecting growing awareness of deployable AI solutions in post-acute care,” said Madison Bush, Director of Corporate Operations at Amesite. “As we expanded NurseMagic™’s capabilities and enterprise offerings, that interest translated into higher engagement across our digital channels, supporting continued momentum leading into the launch of the NurseMagic™ EMR.”
“Reaching this stage reflects the disciplined way we have built NurseMagic™,” said Dr. Ann Marie Sastry, CEO and Founder of Amesite. “With an AI-native EMR, demonstrated enterprise adoption, and a pricing model aligned with patient volumes, we are extending our platform into the core systems that post-acute care organizations depend on. The launch of the NurseMagic™ EMR marks an important step in our strategy to deliver durable, infrastructure-level solutions anchored in customer requirements.”
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven software company focused on delivering technology platform solutions. Its flagship product, NurseMagic™, is designed to streamline clinical documentation, support point-of-care decision-making, and deliver actionable operational insight, and has expanded from an assistant for individual clinicians into an enterprise platform that includes an electronic medical record (EMR) offering. NurseMagic™ is used by used by over 100 professions across all 50 states and over 20 countries. Built on proprietary AI and designed to meet applicable regulatory and security requirements, the platform serves B2B and B2C users with capabilities that include workflow integration and multilingual support.
Forward-Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
Sources
- https://www.mckinsey.com/capabilities/tech-and-ai/our-insights/the-economic-potential-of-generative-ai-the-next-productivity-frontier
- https://www.gminsights.com/industry-analysis/u-s-post-acute-care-market
-
https://www.ama-assn.org/public-health/population-health/hospital-home-saves-lives-and-money-cms-report